Your session is about to expire
← Back to Search
pegsitacianine for Lung Cancer
Phase 2
Waitlist Available
Research Sponsored by OncoNano Medicine, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Biopsy confirmed diagnosis, or a high clinical suspicion of a lung malignancy based on MRI, CT and/or PET imaging
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights
Study Summary
This trial is testing a new cancer treatment where patients are given a single dose of a drug before surgery. The trial is open-label, which means that doctors and patients will know which treatment is being given.
Eligible Conditions
- Lung Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Rate of Patients experiencing at least one Clinically Significant Event (CSE)
Secondary outcome measures
Frequency and Severity of adverse events related to Pegsitacianine
Pegsitacianine fluorescence and imaging performance
Trial Design
1Treatment groups
Experimental Treatment
Group I: Fluorescence imaging with pegsitacianineExperimental Treatment1 Intervention
Pegsitacianine 1 mg/ml infused 24-72 hours prior to surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
pegsitacianine
2021
Completed Phase 2
~80
Find a Location
Who is running the clinical trial?
OncoNano Medicine, Inc.Lead Sponsor
3 Previous Clinical Trials
248 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger